Nanosilica-supported liposome (protocells) as a drug vehicle for cancer therapy

Vinay K Belwal,1 KP Singh1,2 1Bio-Nanotechnology Research Laboratory, Biophysics Unit, CBSH, GB Pant University Agriculture and Technology, Pantnagar, Uttarakhand, 2Department of Molecular Biology, Biotechnology & Bioinformatics, COBSH, CCS Haryana Agriculture University, Hisar, Haryana, In...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Belwal VK, Singh KP
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Mesoporous silica nanoparticles nanovesicles protocells Nano dimensions Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/f8346970fdb94c74acbb919a68cf8e71
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f8346970fdb94c74acbb919a68cf8e71
record_format	dspace
spelling	oai:doaj.org-article:f8346970fdb94c74acbb919a68cf8e712021-12-02T03:08:51ZNanosilica-supported liposome (protocells) as a drug vehicle for cancer therapy1178-2013https://doaj.org/article/f8346970fdb94c74acbb919a68cf8e712018-03-01T00:00:00Zhttps://www.dovepress.com/nanosilica-supported-liposome-protocells-as-a-drug-vehicle-for-cancer--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Vinay K Belwal,1 KP Singh1,2 1Bio-Nanotechnology Research Laboratory, Biophysics Unit, CBSH, GB Pant University Agriculture and Technology, Pantnagar, Uttarakhand, 2Department of Molecular Biology, Biotechnology & Bioinformatics, COBSH, CCS Haryana Agriculture University, Hisar, Haryana, India Abstract: This study encompasses the development and comparison of nanosilica-supported liposome (protocells), conventional liposome, and polyethylene glycol (PEG)-liposome. An effort was made to study the drug encapsulation efficiency and the in vitro release of the drug, and whether protocells (nanovesicles) could sustain the release of the drug by increasing the residence time, which could reduce the dose-related systemic toxicity of the drug, that is, vincristine sulfate. Nanovesicles had a good encapsulation efficiency (71%), which was comparable to the conventional and PEG-liposome, which were 74% and 78%, respectively. The obtained vesicles were in the size range 100–150 nm, and the drug release efficiency of conventional, PEGylated, and protocells liposome was about 67%, 42%, and 52%, respectively, in 150 minutes. The intermediate value of nanosilica-supported liposome indicates the ability for stable and controlled release of the drug, which prevents the rapid burst or slower release of the drug. This study reveals that protocells as nanovesicles could be a better choice for the delivery of cancer drugs such as vincristine sulfate. Keywords: mesoporous silica nanoparticles, nanovesicles, protocells, nanodimensions, nanosilica supported liposomesBelwal VKSingh KPDove Medical PressarticleMesoporous silica nanoparticlesnanovesiclesprotocellsNano dimensionsMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 125-127 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Mesoporous silica nanoparticles nanovesicles protocells Nano dimensions Medicine (General) R5-920
spellingShingle	Mesoporous silica nanoparticles nanovesicles protocells Nano dimensions Medicine (General) R5-920 Belwal VK Singh KP Nanosilica-supported liposome (protocells) as a drug vehicle for cancer therapy
description	Vinay K Belwal,1 KP Singh1,2 1Bio-Nanotechnology Research Laboratory, Biophysics Unit, CBSH, GB Pant University Agriculture and Technology, Pantnagar, Uttarakhand, 2Department of Molecular Biology, Biotechnology & Bioinformatics, COBSH, CCS Haryana Agriculture University, Hisar, Haryana, India Abstract: This study encompasses the development and comparison of nanosilica-supported liposome (protocells), conventional liposome, and polyethylene glycol (PEG)-liposome. An effort was made to study the drug encapsulation efficiency and the in vitro release of the drug, and whether protocells (nanovesicles) could sustain the release of the drug by increasing the residence time, which could reduce the dose-related systemic toxicity of the drug, that is, vincristine sulfate. Nanovesicles had a good encapsulation efficiency (71%), which was comparable to the conventional and PEG-liposome, which were 74% and 78%, respectively. The obtained vesicles were in the size range 100–150 nm, and the drug release efficiency of conventional, PEGylated, and protocells liposome was about 67%, 42%, and 52%, respectively, in 150 minutes. The intermediate value of nanosilica-supported liposome indicates the ability for stable and controlled release of the drug, which prevents the rapid burst or slower release of the drug. This study reveals that protocells as nanovesicles could be a better choice for the delivery of cancer drugs such as vincristine sulfate. Keywords: mesoporous silica nanoparticles, nanovesicles, protocells, nanodimensions, nanosilica supported liposomes
format	article
author	Belwal VK Singh KP
author_facet	Belwal VK Singh KP
author_sort	Belwal VK
title	Nanosilica-supported liposome (protocells) as a drug vehicle for cancer therapy
title_short	Nanosilica-supported liposome (protocells) as a drug vehicle for cancer therapy
title_full	Nanosilica-supported liposome (protocells) as a drug vehicle for cancer therapy
title_fullStr	Nanosilica-supported liposome (protocells) as a drug vehicle for cancer therapy
title_full_unstemmed	Nanosilica-supported liposome (protocells) as a drug vehicle for cancer therapy
title_sort	nanosilica-supported liposome (protocells) as a drug vehicle for cancer therapy
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/f8346970fdb94c74acbb919a68cf8e71
work_keys_str_mv	AT belwalvk nanosilicasupportedliposomeprotocellsasadrugvehicleforcancertherapy AT singhkp nanosilicasupportedliposomeprotocellsasadrugvehicleforcancertherapy
_version_	1718401956361273344

Nanosilica-supported liposome (protocells) as a drug vehicle for cancer therapy

Ejemplares similares